Glioblastoma: Clinical Trials

2,076 trials for Glioblastoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

942 completed, 300 recruiting, 254 terminated, 197 unknown. 881 Phase 2, 819 Phase 1, 242 Not applicable, 109 Phase 3, 88 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 2881Completed 428, Terminated 123, Recruiting 106, Unknown 75, Active not recruiting 74, Withdrawn 36, Not yet recruiting 31, Suspended 6, Enrolling by invitation 2
Phase 1819Completed 409, Terminated 112, Recruiting 104, Active not recruiting 76, Unknown 57, Withdrawn 29, Not yet recruiting 24, Suspended 5, Enrolling by invitation 3
Not applicable242Completed 78, Recruiting 65, Unknown 31, Not yet recruiting 23, Terminated 14, Active not recruiting 13, Withdrawn 13, Suspended 4, Enrolling by invitation 1
Phase 3109Completed 48, Unknown 16, Recruiting 12, Active not recruiting 10, Terminated 10, Not yet recruiting 7, Withdrawn 5, Suspended 1
Early Phase 188Completed 27, Recruiting 19, Terminated 14, Unknown 9, Active not recruiting 7, Not yet recruiting 6, Withdrawn 5, Enrolling by invitation 1
Phase 48Active not recruiting 2, Completed 2, Not yet recruiting 1, Terminated 1, Unknown 1, Withdrawn 1

Follow Glioblastoma: new trials by email Literature Review of Glioblastoma trials Research Report on Glioblastoma

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma
JBI-778 - Brain Metastases From Solid Tumors, Leptomeningeal Disease
Phase 1 / Phase 2Not yet recruitingJubilant Therapeutics Inc.1132028-04-012026-08-07
Metronomic Temozolomide With Dexbrompheniramine for Recurrent High-Grade Glioma/Glioblastoma
Dexbrompheniramine, Temozolomide - High Grade Glioma, Glioblastoma
Phase 1 / Phase 2Not yet recruitingUniversity of Nebraska412027-06-012026-10-05
DLL3 CAR-T Therapy Targeting Brain Tumors
4SCAR DLL3 T cells - Glioblastoma of Cerebellum
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute302027-06-012026-11-02
Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)
ADI-PEG 20 (Arginine deiminase pegylated), Temozolomide (TMZ), Standard of Care Radiation Therapy (RT) - Glioblastoma, High-Grade Glioma (WHO III-IV)
Phase 1 / Phase 2Not yet recruitingSabine Mueller, MD, PhD972027-06-012026-11-09
Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma
Cerebraca wafer, Temozolomide (for relapsed malignant glioma) - Recurrent Glioblastoma, IDH-Wildtype
Phase 2 / Phase 3Not yet recruitingEverfront Biotech Co., Ltd.1752027-04-012026-09-10
Oral Gallium Maltolate for Recurrent Glioblastoma
Gallium Maltolate, Surgical Intervention - Glioblastoma
Early Phase 1Not yet recruitingMedical College of Wisconsin82027-03-012026-09-23
Biomarker-guided RAdiation-deferring Treatment in Younger GBM Patients - Pilot Study
Larotrectinib, Cadonilimab, Plixorafenib - IDH Wildtype Glioblastoma, Glioblastoma (GBM)
Early Phase 1Not yet recruitingOlivia Newton-John Cancer Research Institute122027-03-012026-10-30
FPS-ZM1 With or Without Dexamethasone for Controlling Post Operative Cerebral Edema in Patients With Glioblastoma
Biospecimen Collection, Computed Tomography, Dexamethasone - Glioblastoma, Malignant Glioma
Phase 1Not yet recruitingCity of Hope Medical Center242027-02-172026-08-27
IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas
IDH1-vac, IS-vac, Temozolomide (TMZ) - Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4
Phase 2Not yet recruitingGerman Cancer Research Center2162027-02-012026-10-22
Efficacy of Zoster Vaccination in Glioblastoma Patients
Additional vaccination against shingles (herpes zoster), Standard of care treatment without additional vaccination - Glioblastoma (GBM)
Phase 4Not yet recruitingUniversity Hospital, Essen2302027-01-022026-04-23
NG101m Adjuvant Therapy in Glioblastoma Patients
Intensity-modulated radiation therapy, Temozolomide, NG101m - Glioblastoma Multiforme
Phase 1 / Phase 2Not yet recruitingNeuGATE Theranostics522027-01-012025-10-21
CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM)
CM93 - Glioblastoma
Phase 1Not yet recruitingCrimson Biopharm Inc.722027-01-012024-08-21
Disulfiram/Copper Combination In The Treatment of Newly Diagnosed Glioblastoma Multiform
Temozolomide, Disulfiram, Copper - Glioblastoma Multiforme
Phase 2Not yet recruitingOlympion Medical Center322027-01-012025-05-25
Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma
mirdametinib with radiation, mirdametinib - Neurofibromatosis 1 (NF1)
Phase 2Not yet recruitingUniversity of Alabama at Birmingham552027-01-012026-10-05
ctDNA-Guided Intraventricular Therapy for CNS Malignancies
CSF ctDNA-Guided Clinical Management - Leptomeningeal Disease, Glioblastoma
Not applicableNot yet recruitingAlireza Mansouri772027-01-012026-07-08
IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Newly Diagnosed and Recurrent Pediatric High-grade Glioma (pHGG) and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (ndDIPG)
Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells - High-grade Glioma, Diffuse Intrinsic Pontine Glioma
Phase 1Not yet recruitingUniversity of Florida242027-01-012026-10-30
Adaptive Radiotherapy for Patients With GBM
MRI-Guided Adaptive Radiation Therapy - Glioblastoma
Not applicableNot yet recruitingAbramson Cancer Center at Penn Medicine202027-01-012026-11-12
Immune Modulatory DC Vaccine Against Brain Tumor
Immunomodulatory DC vaccine to target DIPG and GBM - Diffuse Intrinsic Pontine Glioma or Glioblastoma
Phase 1Not yet recruitingShenzhen Geno-Immune Medical Institute102026-12-312026-10-30
Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma
Actinium Ac 225 Lintuzumab, Biospecimen Collection, Cemiplimab - Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma
Phase 1Not yet recruitingNational Cancer Institute (NCI)302026-12-042026-06-12
A Phase I First-in-human Trial of Bvax (B-cell Vaccination) in Addition to Standard of Care Chemoradiotherapy for Newly Diagnosed Glioblastoma
B-cell vaccination - Glioblastoma
Phase 1Not yet recruitingCatalina Lee Chang252026-12-012026-09-25

Showing 20 of 2076. Sign in to see all of them.

Narrower conditions

Brain Neoplasms (603)  ·  Glioma (599)  ·  Gliosarcoma (476)  ·  Astrocytoma (453)  ·  Oligodendroglioma (264)  ·  Central Nervous System Neoplasms (253)  ·  Neoplasms (117)  ·  Ependymoma (108)  ·  Recurrence (72)  ·  Medulloblastoma (70)  ·  Meningioma (55)  ·  Breast Neoplasms (54)  ·  Melanoma (54)  ·  Neuroectodermal Tumors, Primitive (48)

Broader conditions

Neoplasms, Glandular and Epithelial (2073)  ·  Neoplasms by Histologic Type (2070)  ·  Neuroectodermal Tumors (2068)  ·  Neoplasms, Germ Cell and Embryonal (2067)  ·  Neoplasms, Nerve Tissue (2066)  ·  Neoplasms, Neuroepithelial (2057)  ·  Neoplasms (1959)  ·  Astrocytoma (1623)  ·  Glioma (1477)  ·  Neoplasms by Site (819)  ·  Nervous System Diseases (742)  ·  Nervous System Neoplasms (729)  ·  Central Nervous System Diseases (636)  ·  Brain Diseases (635)  ·  Central Nervous System Neoplasms (478)

Interventions

Temozolomide (416)  ·  Radiotherapy (205)  ·  Bevacizumab (160)  ·  Magnetic Resonance Spectroscopy (83)  ·  Radiation (82)  ·  Lomustine (51)  ·  Surgical Procedures, Operative (47)  ·  Carmustine (41)  ·  pembrolizumab (41)  ·  Irinotecan (39)  ·  Specimen Handling (33)  ·  Nivolumab (32)  ·  Carboplatin (27)  ·  Drug Therapy (24)  ·  Erlotinib Hydrochloride (24)

Sponsors

National Cancer Institute (NCI) (120)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (55)  ·  Duke University (52)  ·  M.D. Anderson Cancer Center (43)  ·  Jonsson Comprehensive Cancer Center (27)  ·  City of Hope Medical Center (23)  ·  Mayo Clinic (23)  ·  Case Comprehensive Cancer Center (22)  ·  Memorial Sloan Kettering Cancer Center (21)  ·  Novartis Pharmaceuticals (20)  ·  European Organisation for Research and Treatment of Cancer - EORTC (19)  ·  Washington University School of Medicine (19)  ·  Northwell Health (17)  ·  Northwestern University (17)  ·  Dana-Farber Cancer Institute (16)

Countries

United States (1281)  ·  France (146)  ·  China (133)  ·  Germany (126)  ·  Canada (116)  ·  Spain (92)  ·  Netherlands (91)  ·  Italy (90)  ·  Switzerland (85)  ·  United Kingdom (83)  ·  Australia (66)  ·  Belgium (56)  ·  Austria (37)  ·  South Korea (37)  ·  Denmark (36)

Top investigators

David A. Reardon, MD (15)  ·  Nader Sanai, MD (14)  ·  Annick Desjardins, MD, FRCPC (12)  ·  David Peereboom, MD (12)  ·  John Boockvar, MD (12)  ·  Stuart A. Grossman, MD (12)  ·  Annick Desjardins, MD (8)  ·  Henry S. Friedman, MD (8)  ·  Michael Prados, MD (8)  ·  Katherine B Peters, MD, PhD (7)  ·  Roger Stupp, MD (7)

Results publications

PMID 36346112, PMID 39777725, PMID 15758009, PMID 19269895, PMID 23545055, PMID 24552317, PMID 25113840, PMID 29982805, PMID 32691060, PMID 37540556, PMID 38968568, PMID 12749708, PMID 16520474, PMID 23377664, PMID 23817721, PMID 23940216, PMID 24101040, PMID 24309981, PMID 24344045, PMID 24552318, PMID 24893855, PMID 25098701, PMID 27580889, PMID 27744512, PMID 28039367, PMID 29077941, PMID 32078016, PMID 33842889, PMID 34081125, PMID 34290067, PMID 34331515, PMID 34850166, PMID 35468680, PMID 35569489, PMID 35574391, PMID 37072349, PMID 37142373, PMID 37853118, PMID 38197800, PMID 39571596, PMID 41218853, PMID 41308679, PMID 10334539, PMID 10394416, PMID 10549493, PMID 11410496, PMID 11772431, PMID 11780887, PMID 12573762, PMID 12721262

NIH funding

U01CA062475 (23), P30CA033572 (17), 2023 (12), U01CA137443 (11), U10CA025224 (11), UM1CA137443 (11), U01CA062399 (10), 2009 (8), 2018 (8), P30CA006973 (8), P30CA060553 (8), U10CA021661 (8), U10CA180868 (8), 2015 (7), 2017 (7)